Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InflaRx ( (IFRX) ) just unveiled an update.
On September 11, 2025, InflaRx N.V. announced it regained compliance with Nasdaq’s minimum bid price requirement after its share price met the $1.00 threshold for 10 consecutive business days. This development closes a compliance issue that began on July 11, 2025, when the company was notified of its non-compliance due to a prolonged period of low share prices. Regaining compliance is a positive step for InflaRx, potentially stabilizing its market position and reassuring stakeholders.
The most recent analyst rating on (IFRX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
InflaRx’s overall stock score is primarily impacted by its poor financial performance, characterized by negative profitability and cash flow issues. While technical analysis indicates short-term bullish momentum, the stock’s valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call data and corporate events further limits the assessment.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company based in Jena, Germany, specializing in anti-inflammatory therapeutics. The company focuses on developing inhibitors of the complement activation factor C5a and its receptor, with products such as vilobelimab, an anti-C5a monoclonal antibody, and INF904, a small molecule inhibitor. Founded in 2007, InflaRx operates offices in Germany and the USA.
Average Trading Volume: 504,632
Technical Sentiment Signal: Hold
Current Market Cap: $98.69M
For an in-depth examination of IFRX stock, go to TipRanks’ Overview page.